Premium
CCNU (lomustine), idarubicin and dexamethasone (CIDEX): an effective oral regimen for the treatment of refractory or relapsed myeloma
Author(s) -
Parameswaran R.,
Giles Chrissy,
Boots M.,
Littlewood T. J.,
Mills M. J.,
Kelsey S. M.,
Samson Diana
Publication year - 2000
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2000.02082.x
Subject(s) - lomustine , idarubicin , medicine , dexamethasone , oncology , regimen , refractory (planetary science) , multiple myeloma , chemotherapy , cytarabine , vincristine , physics , astrobiology , cyclophosphamide
We report the results of a non‐randomized pilot study of an oral regimen comprising CCNU (lomustine; 25 or 50 mg/m 2 on day 1), idarubicin (4‐demethoxydaunorubicin) (10 mg/m 2 on days 1–3) and dexamethasone (10 mg b.d. on days 1–4) in patients with relapsed or refractory myeloma. Treatment was given every 28 d for a maximum of six courses. Sixty patients were entered of whom 57 were evaluable. Overall response rate (partial or minor response) was 49% with 30% of patients achieving a partial response (50% tumour reduction). Response rates were higher in patients with untested relapse than in those with refractory disease (overall response rates 56% vs. 31%). The major toxicity was neutropenia and the regimen was otherwise well tolerated. The median survival from entry of all patients was 15 months, with 30% of patients alive at 2 years. This regimen represents a useful addition to available treatment options.